Literature DB >> 32271879

Combined deletion of Bap1, Nf2, and Cdkn2ab causes rapid onset of malignant mesothelioma in mice.

Jitendra Badhai1, Gaurav Kumar Pandey1, Ji-Ying Song2, Oscar Krijgsman3, Rajith Bhaskaran1, Gayathri Chandrasekaran1, Min-Chul Kwon4, Lorenzo Bombardelli1, Kim Monkhorst5, Cristoforo Grasso4, John Zevenhoven4, Jan van der Vliet4, Miranda Cozijnsen4, Paul Krimpenfort4, Daniel Peeper3, Maarten van Lohuizen1, Anton Berns1.   

Abstract

We have generated mouse models of malignant mesothelioma (MM) based upon disruption of the Bap1, Nf2, and Cdkn2ab tumor suppressor loci in various combinations as also frequently observed in human MM. Inactivation of all three loci in the mesothelial lining of the thoracic cavity leads to a highly aggressive MM that recapitulates the histological features and gene expression profile observed in human patients. The tumors also show a similar inflammatory phenotype. Bap1 deletion alone does not cause MM but dramatically accelerates MM development when combined with Nf2 and Cdkn2ab (hereafter BNC) disruption. The accelerated tumor development is accompanied by increased Polycomb repression and EZH2-mediated redistribution of H3K27me3 toward promoter sites with concomitant activation of PI3K and MAPK pathways. Treatment of BNC tumor-bearing mice with cisplatin and pemetrexed, the current frontline treatment, prolongs survival. This makes the autochthonous mouse model described here very well suited to explore the pathogenesis of MM and validate new treatment regimens for MM, including immunotherapy.
© 2020 Badhai et al.

Entities:  

Year:  2020        PMID: 32271879     DOI: 10.1084/jem.20191257

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  7 in total

1.  Mesothelioma Mouse Models with Mixed Genomic States of Chromosome and Microsatellite Instability.

Authors:  Yurong Song; Shaneen S Baxter; Lisheng Dai; Chelsea Sanders; Sandra Burkett; Ryan N Baugher; Stephanie D Mellott; Todd B Young; Heidi E Lawhorn; Simone Difilippantonio; Baktiar Karim; Yuwaraj Kadariya; Ligia A Pinto; Joseph R Testa; Robert H Shoemaker
Journal:  Cancers (Basel)       Date:  2022-06-24       Impact factor: 6.575

Review 2.  Roles and mechanisms of BAP1 deubiquitinase in tumor suppression.

Authors:  Louis Masclef; Oumaima Ahmed; Benjamin Estavoyer; Bruno Larrivée; Nathalie Labrecque; Anastasia Nijnik; El Bachir Affar
Journal:  Cell Death Differ       Date:  2021-01-18       Impact factor: 12.067

3.  Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches-a narrative review.

Authors:  Alicia A Zolondick; Giovanni Gaudino; Jiaming Xue; Harvey I Pass; Michele Carbone; Haining Yang
Journal:  Precis Cancer Med       Date:  2021-09-30

4.  Activation of DNA Damage Tolerance Pathways May Improve Immunotherapy of Mesothelioma.

Authors:  Hélène Brossel; Alexis Fontaine; Clotilde Hoyos; Majeed Jamakhani; Mégane Willems; Malik Hamaidia; Luc Willems
Journal:  Cancers (Basel)       Date:  2021-06-27       Impact factor: 6.639

Review 5.  Mouse models for mesothelioma drug discovery and development.

Authors:  Kenneth P Seastedt; Nathanael Pruett; Chuong D Hoang
Journal:  Expert Opin Drug Discov       Date:  2020-12-31       Impact factor: 7.050

Review 6.  Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer.

Authors:  Michele Carbone; J William Harbour; James Brugarolas; Angela Bononi; Ian Pagano; Anwesha Dey; Thomas Krausz; Harvey I Pass; Haining Yang; Giovanni Gaudino
Journal:  Cancer Discov       Date:  2020-07-20       Impact factor: 38.272

Review 7.  Use of preclinical models for malignant pleural mesothelioma.

Authors:  Marie Shamseddin; Joanna Obacz; Mathew J Garnett; Robert Campbell Rintoul; Hayley Elizabeth Francies; Stefan John Marciniak
Journal:  Thorax       Date:  2021-03-10       Impact factor: 9.139

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.